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ARTICLE
Genetic Mapping at 3-Kilobase Resolution Reveals Inositol
1,4,5-Triphosphate Receptor 3 as a Risk Factor for Type 1
Diabetes in Sweden
Jared C. Roach, Kerry Deutsch, Sarah Li, Andrew F. Siegel, Lynn M. Bekris, Derek C. Einhaus,
Colleen M. Sheridan, Gustavo Glusman, Leroy Hood, A˚ke Lernmark, and Marta Janer,
on behalf of the Swedish Childhood Diabetes Study Group and the Diabetes Incidence in Sweden
Study Group
We mapped the genetic inﬂuences for type 1 diabetes (T1D), using 2,360 single-nucleotide polymorphism (SNP) markers
in the 4.4-Mb human major histocompatibility complex (MHC) locus and the adjacent 493 kb centromeric to the MHC,
initially in a survey of 363 Swedish T1D cases and controls. We conﬁrmed prior studies showing association with T1D
in the MHC, most signiﬁcantly near HLA-DR/DQ. In the region centromeric to the MHC, we identiﬁed a peak of
association within the inositol 1,4,5-triphosphate receptor 3 gene (ITPR3; formerly IP3R3). The most signiﬁcant single
SNP in this region was at the center of the ITPR3 peak of association ( for the survey study). For validation,54Pp 1.7# 10
we typed an additional 761 Swedish individuals. The P value for association computed from all 1,124 individuals was
(recessive odds ratio 2.5; 95% conﬁdence interval [CI] 1.7–3.9). The estimated population-attributable risk561.30# 10
of 21.6% (95% CI 10.0%–31.0%) suggests that variation within ITPR3 reﬂects an important contribution to T1D in
Sweden. Two-locus regression analysis supports an inﬂuence of ITPR3 variation on T1D that is distinct from that of any
MHC class II gene.
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Type 1 diabetes (T1D [MIM 222100]) is the most common
chronic disease in children and affects ∼1% of the pop-
ulation in high-incidence countries, such as those of Scan-
dinavia. The incidence of T1D is increasing worldwide by
2%–5% per year.1 The disease is due to an autoimmune
destruction of pancreatic islet b cells and is associatedwith
cellular and humoral immunological abnormalities.2 Pa-
tients become insulin dependent for life; often develop
late complications that include angiopathy, nephropathy,
retinopathy, and neuropathy; and have a shortened life
expectancy. The genetic etiology of T1D is strongly as-
sociated and genetically linked with the HLA-DR/DQ lo-
cus.3 Numerous investigations have identiﬁed the contri-
bution ofmajor histocompatibility complex (MHC) genes.
These have included both association and linkage stud-
ies.4–6 The relative risk of siblings with associated allele
sharing at the HLA-DR/DQ locus (also known as “IDDM1”)
has been estimated to be 2.5–3.4.7 As a result of the as-
sociation of the MHC locus with T1D, Concannon et al.3
called for MHC studies employing SNPs at a high density.
In addition to the MHC class II genes, other genes in
or near the MHC locus have long been suspected to con-
tribute to T1D risk.8 Four lines of evidence have fueled
these suspicions. First, genes currently known to be as-
sociated with T1D risk account for only a portion of the
genetic risk, implying that more genes remain to be iden-
tiﬁed. Second, despite extensive genomewide scans for
risk, the only span consistently identiﬁedwith a high LOD
score is centered in the MHC locus.9,10 This singular high
but broad peak of association has led to the suspicion that
at least one additional risk gene, in addition to the MHC
class II genes, lies within this region. Third, higher-reso-
lution linkage analysis in some MHC studies has shown
multiple local maxima, suggesting that multiple genes
might contribute.11 Fourth, dissection of the diabetes phe-
notype of the nonobese diabetic mouse has demonstrated
distinct and separable genetic loci contributing to diabetes
risk. In particular, Deyrutter et al.12 used congenic mice to
isolate and reﬁne the localization of Idd16 to a 3.1-Mb
region. This locus predisposes to diabetes in the mouse
distinctly from the MHC class II association. In humans,
the region syntenic to Idd16 lies immediately centromeric
to the MHC locus. This region was the focus of our current
study.
In previous studies, the extended linkage disequilibrium
(LD) in the MHC has made it difﬁcult to prove that other
associations in or near the MHC are independent and not
explained by LD with HLA-DR/DQ. There are two reasons
for this limit on resolution: (1) markers were spaced too
far apart to resolve separate peaks of association, and (2)
LD broadens and alters peaks of association.13 In our study,
we have overcome the ﬁrst limitation but not the second.
Therefore, we still are unable to resolve separate etiologic
inﬂuences within the MHC, if indeed there is more than
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Table 1. Overview of Samples, Originally Collected
in DIS or SCDS
Study and Measure Cases Controls
Survey:
No. of individuals: 181 182
Females 79 92
Males 102 90
Age at diagnosisa (years):
Range 1.83–34.58 1.25–35.33
Mean 16.5 17.5
Median 15.2 14.9
No. of DIS individuals 92 90
No. of SCDS individuals 89 92
Survey and validation combined:
No. of individuals: 651 483
Females 268 236
Males 383 247
Age at diagnosisa (years):
Range 1.25–34.58 1.25–35.33
Mean 15.9 16.0
Median 13.8 13.6
No. of DIS individuals 281 179
No. of SCDS individuals 370 304
a Age at diagnosis for controls refers to age at diagnosis of the case
patient to whom the control was birth matched.
one. However, we can now resolve peaks of association
that lie near the MHC, as long as they lie outside the span
of strong LD of the MHC locus, and we have identiﬁed
one such peak in the inositol 1,4,5-triphosphate receptor
3 gene (ITPR3 [MIM 147267]).
This article ﬁrst reports the results of our survey study
of 363 individuals typed for 2,260 markers covering both
the MHC locus (4,419,819 bp; 2,114 SNPs) and the region
immediately centromeric (493,457 bp; 146 SNPs). The sur-
vey study unexpectedly identiﬁed a novel association in
the centromeric region within the ITPR3 gene, so our ex-
position next presents analyses of the statistical signiﬁ-
cance of this association based only on the survey data.
After considering these data, our team made the decision
to test this association in a veriﬁcation study of an addi-
tional 761 individuals. To increase the power of the ver-
iﬁcation study, it was performed only on markers within
the initially identiﬁed ITPR3 peak of association. Our ex-
position concludes with an analysis of the data from our
veriﬁcation study and the conclusion that ITPR3 is asso-
ciated with T1D.
Material and Methods
Study Selection
DNA samples for both our survey and veriﬁcation studies are a
subset of the samples collected and analyzed previously for the
Diabetes Incidence in Sweden Study (DIS) and the Swedish Child-
hood Diabetes Study (SCDS).4,14,15 DIS was a case-control study of
diabetes of all types in 15–34-year-olds from January 1987 to
December 1988. DIS included 474 patients with T1D and 279
controls. We did not select any patients without T1D from DIS
for analysis in the present study (i.e., we did not include those
with type 2 diabetes [T2D {MIM 125853}]). SCDS was a matched
case-control study of T1D in 0–14-year-olds from September 1986
to December 1987 and included 498 subjects with T1D and 423
controls. The majority (88%) of the controls in SCDS were
matched by date of birth, region of birth, and sex. Further details
for SCDS and DIS are as described by Graham et al.16 The ho-
mogeneity of the Swedish population makes it unlikely that pop-
ulation stratiﬁcation or admixture confounded our study. For our
study, only samples over a threshold of available micrograms of
DNA were selected for analysis, to maximally preserve the DNA
banked resource. Because each original matched control sample
was not always available, we selected our controls from those
available, with the primary criterion of matching them by age to
the cases. As a result, we introduced a slight sex differential be-
tween our cases and controls. For our survey study, 368 samples
were selected for typing with the Illumina MHC SNP set. Typing
failed for 5 of our 368 samples, so data analysis was performed
on the remaining 363 samples (table 1). We do not suspect any
bias inﬂuencing which samples failed. For our veriﬁcation study,
we typed 771 distinct additional samples for 40 SNPs. Of these,
761 were successfully typed for SNP rs2296336, which is repre-
sentative of the success rate for our Sequenom veriﬁcation ge-
notyping of these samples. During veriﬁcation, we also retyped
most of the samples previously typed with Illumina technology
and were thus able to cross-validate the results of the two tech-
nologies. The union of the sets of samples we typed with the
Sequenom technology or the Illumina technology totals 1,134
samples. Samples that failed typing by Illumina but were suc-
cessfully typed by Sequenom technology were included in the set
of 771 distinct additional samples. The number of failures of Il-
lumina typing at each locus was typically zero to three samples
but, in some instances, was as high as eight samples.
SNP Typing
The MHC Panel Set implemented by Illumina was used to type
all the samples in our survey study (but not in the validation
study). The Illumina call-rate statistics for each locus typed are
available at T1DBase—ITPR3. Development of SNPs selected for
this panel leveraged both the MAGMA software for SNP selection
and algorithms for maximizing linkage information.17–19 The
panel is described in the MHC Panel Set Datasheet (available at
the Illumina: MHC Mapping Panel Web site) and includes (1)
1,293 SNPs evenly spaced across the MHC region, (2) 1,228 SNPs
in or near coding regions, and (3) additional SNPs designed to
tag haplotype blocks (tSNPs). The sequences and mapped loca-
tions of these SNPs are available at T1DBase—ITPR3. The distri-
bution of SNPs includes ∼30% that are 110 kb from known coding
regions, 20% in introns, and ∼40% !10 kb from coding regions;
the remaining SNPs are in transcribed regions, including both
coding regions and UTRs. SNPs were typed with bead-based as-
says, with each bead afﬁxed to the end of a glass ﬁber, to enable
optical readout of a proprietary extension/ligation reaction (de-
tails available at the Illumina: Technology and Applications Web
site). The total region covered by this set of SNPs was selected by
Illumina to have broad applicability for a number of purposes
but was designed in part to implement ﬁne-scale associationmap-
ping of the MHC, with speciﬁc consideration of the T1D candi-
date region in the MHC. The set of SNPs covers a span of the
MHC from the gene RFP (MIM 602165) to the gene KNSL2 (MIM
603763), which has been termed “the extended MHC locus,” and
includes additional SNPs centromeric to the extendedMHC locus,
for a total of 2,360 SNPs. The total of 2,360 was determined in
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part by the quanta imposed by the implementation of Illumina
technology. In particular, the centromeric bound on the region
covered by our SNPs lies just beyond the ITPR3 gene. There are
at least two limitations of the IlluminaMHC SNP Set. First, despite
the generally uniform high tiling density, there are some large
spacings between SNPs. Second, some particularly important
spacings are fairly long. For example, the spacing containingHLA-
DQB1 is 8,381 bp. We did not extend typing tomore-centromeric
SNPs because that was the limit of the Illumina MHC SNP Set
and because we did not expect to ﬁnd an association beyond this
limit.
We searched for evidence of assay-speciﬁc technical failures in
our Illumina survey data by computing P values for Hardy-Wein-
berg equilibrium in our control population of 182 Swedish in-
dividuals. The distribution of P values showed no outliers; in
particular, of the 2,360 P values, 52 were !.05 and 12 were !.01.
In determining which SNPs to display in ﬁgure 1C,we required
that each of the three possible genotypes be seen at least 10 times
in our survey data set of 363 individuals. This ﬁlter protects
against the possibility of error introduced by technical issues spe-
ciﬁc to the typing of that particular SNP (e.g., high optical noise)
but might exclude some informative SNPs with low minor-allele
frequencies (MAFs). However, these excluded SNPs have low
power because of their low MAF. As a result of this ﬁlter, 1,696
SNPs are plotted in ﬁgure 1C.
For our veriﬁcation study, typing was performed for 40 SNPs
with theMassArray genotyping system (Sequenom),which is cen-
tered on a chip-based matrix-assisted laser desorption/ioniza-
tion time-of-ﬂight (MALDI-TOF) mass spectrometer. The SNPs
were selected to span the 180,552-bp interval containing the
ITPR3 gene. Multiplex SNP assays were designed using Spectro-
DESIGNER 3.0. The 40 SNPs were genotyped in four sets. Two
sets were typed using IPLEX chemistry, and two sets were typed
using Homogeneous MassEXTEND (HME) chemistry. In both
cases, 384-well plates containing 5–10 ng of DNA in each well
were PCR ampliﬁed per Sequenom’s speciﬁcations. After PCR,
Arctic shrimp alkaline phosphatase was added to samples to pre-
vent further incorporation and interference with the primer-
extension assay. Allele-discrimination reactions with the use of
HME chemistry were conducted by addition of extensionprimers,
DNA polymerase, and a cocktail mixture of deoxynucleotide
triphosphates (dNTPs) and dideoxynucleotide triphosphates
(ddNTPs) to each well.20 For IPLEX reactions, the dNTP-ddNTP
mixture was substituted with a mixture of modiﬁed ddNTPs.21
After the primer-extension step, MassEXTEND clean resin was
added to the mixture to remove extraneous salts that could in-
terfere with MALDI-TOF analysis. Genotypes were determined by
spotting 15 nl of each sample onto a 384 SpectroCHIP, which
was subsequently read by the MALDI-TOF mass spectrometer. Of
the 40 attempted SNPs, 28 were successful in that they both (1)
had a technically successful assay, as indicated by distinct clus-
tering of the signals for the three different genotypes, and (2)
had a nonzero MAF in our samples. Of these 28 SNPs, 18 were
present in the Illumina MHC SNP set employed in the survey
study and 10 were not (table 2). SNPs rs6912568, rs2296333,
rs9461899, rs9469559, and rs2229641 were invariant in our sam-
ples, and SNPs rs11963294 and rs2229633 had a low MAF—these
SNPs are not shown in table 2.
SNP Mapping
All SNPs were selected from or have been assigned identiﬁers in
dbSNP. SNPs were localized to all known genomic sequences de-
rived from human MHC loci (listed at T1DBase—ITPR3). These
genomic sequences included: (1) the published sequences of two
haplotypes of the MHC22; (2) all clones sequenced by the Sanger
Centre as part of the MHC haplotype project, in accordance with
the assignments provided by the Sanger Centre to one of eight
haplotypes: PGF, COX, APD, DBB, MANN, SSTO, QBL, and MCF;
(3) all genomic sequences 110 kb with signiﬁcant BLAST scores
matching the Sanger MHC assembly; (4) the two alternative ver-
sions of the MHC region in the University of California–Santa
Cruz (UCSC) May 2004 human assembly (chr6_hla_hap1 and
chr6_hla_hap2) (MGC/ORFenomes Genome Browser); and (5)
the UCSC–National Center for Biotechnology Information
(NCBI) consensus sequence. The complete sequences of PGF and
COX are reported by Stewart et al.22 SNPs were also mapped to
known variations in IMGT/HLA. The use of multiple reference
sequences allowed SNPs to be assigned to different positions in
different haplotypes, when haplotype information was known.
Some SNPs may not be present in some haplotypes (e.g., the
contextual sequence is missing or altered in such a way that the
assay, depending on implementation, always provides a negative
or ambiguous result for that haplotype).
The SNP rs701831 maps to locations 3625544, 3687731, and
3660864, with respect to the origin shown in ﬁgure 1. This reﬂects
the repeat structure of the region. Because these positions are
fairly close, we portray this SNP only once, at position 3660864,
to avoid creating a visual illusion of more statistical signiﬁcance
than our data justify. The SNP rs3131635 maps to two locations:
2614465 and 2519595. The score of rs3131635 correlates much
better with its neighbors at position 2614465 than at 2519595,
so we reject the positioning at 2519595 on the basis of this evi-
dence and portray only position 261446 in ﬁgure 1. The SNP
rs3130914 maps to only one location on the canonical reference
sequence but maps to two locations on most haplotypes, includ-
ing the Sanger MHC reference sequence (The MHC Haplotype
Project Web site), CX, DB, MC, and SS. If one were to arbitrarily
assign it to the single location it exactlymatches on the canonical
reference sequence, it would represent a local maximum and pos-
sibly alter the interpretation of results. However, assigning it to
its other location places it below an inferred dynamic baseline,
and thus it appears to be a less interesting marker. In ﬁgure 1,
we plot this SNP at this less interesting location, just 5′ of MICB
(MIM 602436). Thus, an understanding of the sequence varia-
tions that inﬂuence the apparent genetic position of SNPs is im-
portant for the interpretation of this SNP and will become in-
creasingly important as more haplotypic sequence information
becomes known for the MHC locus.
Statistical Analysis
Hardy-Weinberg equilibrium and LD statistics were computed
with HWE and LD (Cran—Package genetics), packages by Warnes
and Leisch implemented in The R Project for Statistical Com-
puting. Single-point association scores were calculated from
genotype contingency tables by use of Fisher’s test, as im-3 # 2
plemented in R. Odds ratios (ORs) and 95% CIs were computed
with the R package EpiTools (Arago´n). Population-attributable
risks (PARs) were computed as follows:
Figure 1. Association with T1D at ITPR3. A, Long-range LD is plotted as a function of r2 between all pairs of SNPs (only is2r  0.7
displayed); the resulting LD plot derived from our study population controls is similar to plots from other studies. The r2 value between
a pair of SNPs is plotted at the apex of an isosceles right triangle deﬁned by the baseline connecting the SNPs. B, Locations of genes
in and near the MHC, provided for reference. Not all genes are shown. R p recombination hotspot; S p syntenic breakpoint between
mouse and other mammalian genomes. C, Single-point associations between T1D and SNPs in the Illumina MHC Panel. If at least one
allele of a SNP exactly matches this canonical reference, it is blackened; otherwise, the SNP is shaded gray. The Y-axis is in units of
log10(P). SNPs inside a box are selected to be illustrative of a peak of association. The Tsp linkage statistic is described by Herr et
al.11 Gray bars indicate microsatellites typed by Herr et al.11 (the microsatellite D6S1629 with Tsp is ∼13 kb centromeric log (P)p .61
to the right margin of the ﬁg.). The X-axis is the same for all graphs and is indexed to base pairs of the May 2004 human genome
build.
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Table 2. Veriﬁcation of ITPR3 SNP Genotypes
Locus
Typed in
Survey
Study
Covered by
Sequencing
Chromosome 6
Position
P for Cases Controls
All
Data
Survey
Dataa AA AB BB AA AB BB
rs10947415 No No 33699761 .237 ND 443 163 14 309 129 17
rs4711332 Yes No 33703376 .912 .236 12 149 466 8 117 349
rs10947418 No No 33712995 .364 ND 15 163 442 16 130 309
rs4713646 Yes No 33714500 .00200 .0851 51 255 336 22 159 297
rs12205634 Yes No 33719644 .0368 .0186 385 203 25 265 177 31
rs6457738 Yes No 33725441 .505 .195 249 304 83 173 226 72
rs1570760 Yes No 33730910 .0897 .0158 30 221 374 33 185 256
rs5875456 No No 33732282 .106 ND 29 225 373 31 178 245
rs2296343 Yes No 33734694 2.95 # 104 .00182 264 265 93 241 193 37
rs2296337 Yes No 33739673 1.98 # 104 9.12 # 104 92 267 281 34 194 248
rs1536036 Yes No 33739991 .0149 .00891 195 285 148 110 237 127
rs6901411 No No 33741504 6.24 # 104 ND 266 261 91 234 183 36
rs9357163 No Yes 33742614 .120 ND 456 142 16 308 128 13
rs12195707 No Yes 33744024 .189 ND 16 149 453 20 118 318
rs9380372 No Yes 33744210 2.12 # 104 ND 4 147 455 14 142 298
rs2296336 Yes Yes 33744638 1.30 # 106 1.70 # 104 107 296 240 35 217 229
rs2077163 Yes Yes 33744884 5.30 # 104 .00692 215 321 96 123 241 110
rs2229634 Yes Yes 33746157 6.69 # 106 1.82 # 104 100 314 236 36 216 228
rs2274198 No Yes 33746635 1.69 # 106 ND 116 293 207 41 212 204
rs3736893 Yes Yes 33747737 .00138 .0372 327 256 62 191 225 62
rs2274197 Yes No 33753092 .125 .0257 28 226 373 33 178 260
rs2229638 Yes No 33756205 .448 .603 472 117 6 377 76 5
rs12528378 No No 33761463 .0182 ND 45 51 516 56 39 355
rs3818521 Yes No 33765223 .123 .871 157 319 151 96 242 132
rs2229642 No No 33767449 .112 ND 137 327 171 122 234 106
rs3818527 Yes No 33769012 .181 .891 154 336 152 100 239 134
rs2281919 Yes No 33771148 .220 .240 453 161 18 319 142 16
rs2281816 Yes No 33880313 3.39 # 104 .0204 269 285 83 231 213 29
NOTE.—These data conﬁrmed the results of our survey study—that ITPR3 is associated with T1D. An index of the allele sequences is provided at
T1DBase—ITPR3.
a ND p no data.
Type Cases Controls
Risk a b
Protective c d
b
P ≈con b d
ad′OR p
bc
′P (OR  1)conPAR% ≈ # 100 ,′P (OR  1) 1con
where Pcon is the probability of a control having the risk genotype,
OR′ is a formula for computing the OR, and PAR% is the PAR
percentage.
ORs approximate genotype relative risks. For example, the OR
for RR:PP (where R is the risk allele and P is the protective allele)
approximates the genotype relative risk appropriate for a recessive
model. The PAR we compute is for both the heterozygous and
homozygous risk genotypes (e.g., a in the above equations is the
sum of the number of cases that are homozygous for risk alleles
and the number of cases that are heterozygous).
Multiple-Test Correction
No multiple-test correction has been applied to the P values of
the 1,696 plotted SNP scores in ﬁgure 1C. To estimate the prob-
ability of type I error associated with identiﬁcation of the peak
of association in ITPR3 in our survey study, we implemented a
permutation multiple-test correction for the region centromeric
to the MHC.23 We deﬁned a signiﬁcant peak as a contiguous set
of nine SNPs, of which seven had a single-point association P !
and three had . This reﬂects the characteristics of the.01 P ! .001
peak we identiﬁed at ITPR3, using standard statistical P value
cutoffs. We then estimated the probability of type I error by per-
muting the case-control labels on our survey data 1,000 times
and enumerating the number of iterations in which such a peak
was observed. No correction was applied to the validation study,
since all 28 validation SNPs were selected because they lie within
the peak of association encompassing ITPR3 and are thus highly
correlated and because an a priori decision was made for the
primary analysis to be based on the typing of the single SNP at
the peak of the survey association, rs2296336.
Sequencing
After evaluation by 1% agarose gel electrophoresis, templates
were puriﬁed with Millipore ﬁltration. Sequencing reactions were
performed in the Institute for Systems Biology core sequencing
facility by use of ABI 3730 capillary sequencers. Chromatograms
were assembled and visualized with VectorNTI (Invitrogen).
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Bioinformatics
Our convention for genomic coordinates for this article is the
May 2004 human genome assembly. We interpreted our data in
the context of reference information on T1D genetics found in
the confederated database T1DBase.24 Input ﬁles for Haploview
that permit exploration of the characteristics of LD in our study
population are available at T1DBase—ITPR3.25 Files are also avail-
able at T1DBase—ITPR3 that provide coding for MHC class II
alleles as biallelic markers, permitting Haploview visualization
of the amount of LD between speciﬁc MHC class II alleles and
ITPR3 in our veriﬁcation control population. We employed
PHASE v2.1.1 to infer haplotypes.26 Regression analysis was per-
formed with LRASSOC 1.1.27 The full model implemented in
LRASSOC is of the form log [r / (1 r)]p m a x  d z  a x 1 1 1 1 2 2
. The probability r that ad z  i x x  i x z  i z x  i z z2 2 aa 1 2 ad 1 2 da 1 2 dd 1 2
subject with the given genotype represents a case rather than a
control is modeled from the dummy variables x and z that specify
genotype. The parameters to be estimated consist of the mean
term m, terms to model additive effects a1 and a2 at each locus,
terms to model dominance effects d1 and d2, and terms to model
interactive effects , , , and . In addition to the full model,i i i iaa ad da dd
LRASSOC ﬁts eight models with fewer parameters: MEAN (m),
ADD1 (m, a1), ADD2 (m, a2), ADD (m, a1, a2), DOM1 (m, a1, d1),
DOM2 (m, a2, d2), DOM (m, a1, d1, a2, d2), and ADDDOM (m, a1, d1,
a2, d2, , , ).i i iaa ad da
Resolution
We mapped SNPs to 2,402 genomic positions with 2,401 corre-
sponding spacings. A few of our 2,360 SNPs mapped to more
than one position. The mean spacing was 2,046 bp, the median
was 1,347 bp, and the minimum was 5 bp. The size of the longest
spacing was 59,292 bp, between rs389512 and rs6474; this spacing
contains C4A (MIM 120810) in tandem duplication. There was a
total of 31 other spacings 110 kb, which ranged from 10,030 bp
to 39,868 bp. The use of a reference haplotype other than the
May 2004 assembly could alter some of the reported spacings.
We refer to the resolution of our methodology as “3-kb.” Given
the actual value of the mean spacing, we may have been justiﬁed
in claiming a 2-kb resolution. However, given that not all SNPs
are equally powerful and that the mean spacing does not alone
summarize the spacing distribution, we refer to our resolution
more conservatively as a 3-kb resolution.
Because the selection of SNPs for the Illumina MHC SNP set
included an additional focus on coding regions, the coding
regions have an increased density of SNPs. In ﬁgure 1C, one visual
effect of this higher density is an increase in the range of SNP P
values for coding regions but not in the underlying distribution
of P values. The opposite effect is true for highly polymorphic
coding regions, where, despite increased scrutiny, no suitable uni-
versal primers could be found.28
Results
We applied a high-density SNP panel to a collection of
carefully selected T1D cases and controls from DIS and
SCDS, to test the hypothesis that genetic factors besides
HLA-DR/DQ may contribute to the risk of T1D.4,15 The
tiling of our SNPs was designed to be at least an order of
magnitude denser than the expectedminimal spans of LD,
to (1) permit increased levels of conﬁdence for the asso-
ciations found by leveraging association trends among
SNPs in LD and (2) use increased resolution to distinguish
separate peaks of association. A particular goal was to nar-
row the search for etiologies of T1D genetically coded in
or centromeric to the MHC. In our initial survey, we typed
181 Swedish T1D cases and 182 controls for the 2,360
densely spaced SNP markers that comprise the Illumina
MHC SNP set.
We computed single-marker associations between each
of our typed SNPs and T1D by calculating P values with
Fisher’s exact method from contingency tables of3# 2
case and control genotypes (ﬁg. 1). These are also provided
as a table of markers, locations, and P values at T1DBase—
ITPR3. We identiﬁed two peaks in this region that might
represent independent associations with T1D. One of
these peaks, HLA-DR/DQ, is a reconﬁrmation of a well-
recognized association.3 As can be seen in graphics of long-
range LD (ﬁg. 1A and a Haploview analysis of the same
data at T1DBase—ITPR3), the nearly 3-Mb telomeric tail
of this peak covering the MHC locus can be explained by
LD. The second peak is contained within the ITPR3 gene.
It is neither within the MHC nor in a region of extended
LD. It is sharp and constrained to a short interval.
In our initial survey, the SNP with the most signiﬁcant
association (survey ) lies in an intron of17Pp 2.4# 10
HLA-DQA1 (MIM 146880). The dbSNP accession number
for this SNP is rs9272723. The ITPR3 peak is represented
most signiﬁcantly by the SNP rs2296336 (survey Pp
). This SNP is located at chromosome 6 position41.7# 10
33744638, in an intron of ITPR3. We applied a permuta-
tion multiple-test correction to the ITPR3 peak and ob-
served a peak meeting the signiﬁcance criteria in a single
iteration of 1,000, suggesting a corrected P value for the
peak of ∼.001 (ﬁg. 2). We computed ORs to measure the
strength of association for each SNP in our survey (avail-
able in a table at T1DBase—ITPR3). The survey OR for
rs9272723 was 5.8 (95% CI 3.8–9.1). The survey OR for
rs2296336 was 1.8 (95% CI 1.3–2.5). After all global anal-
yses were performed, we separately analyzed the male and
female subgroups; in both instances, we observed a peak
of association at the ITPR3 gene (data not shown).
We employed Monte Carlo analysis to estimate the
power of our survey study of 363 individuals to detect an
effect similar to the effect we observed for rs2296336. We
simulated 1,000 sets of data for a single locus, with the
case genotype frequencies drawn from a trinomial distri-
bution reﬂecting the observed case frequencies, the ob-
served control frequencies, or nine intermediate fre-
quency sets (table 3). In all cases, the frequencies of the
simulated control genotypes were the frequencies of the
observed control genotypes for all rows. These simulations
suggest that our survey study was adequately powered to
observe an effect of ITPR3 on T1D of the strength observed
in Sweden but may not have had the power to observe
much weaker effects.
Associations between T1D and non–class II geneswithin
the MHC have a low likelihood of representing a causal
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Table 3. Power of Survey Study of 363 Individuals
to Detect an Effect Similar to That Observed at ITPR3,
as Computed by Monte Carlo Analysis
Subject
Group
Case
Genotype
Ratios
Determining
Frequencies
No. of Simulated Survey
Studies with P !
.05 .01 .001 .000168 .0001
Cases 39:81:61 993 958 790 558 469
Intermediate 1 36:81:63 981 880 573 321 257
Intermediate 2 34:82:66 944 751 364 154 120
Intermediate 3 31:82:68 816 570 184 51 38
Intermediate 4 29:82:71 682 348 65 11 6
Intermediate 5 26:83:73 449 168 23 4 1
Intermediate 6 23:83:75 263 62 2 0 0
Intermediate 7 21:83:78 85 8 0 0 0
Intermediate 8 18:83:80 29 3 0 0 0
Intermediate 9 16:84:83 4 0 0 0 0
Controls 13:84:85 4 0 0 0 0
NOTE.—Each row represents the result of 1,000 simulations of data for
a single locus, with the case genotype frequencies drawn from a trinomial
distribution reﬂecting the observed case frequencies (top row of data),
the observed control frequencies (bottom row), or nine intermediate
frequency sets. The frequencies of the simulated control genotypes were
the frequencies of the observed control genotypes for all rows. As ex-
pected, approximately half of the time (558 of 1,000 simulations), we
would have observed a more signiﬁcant P value than we actually did for
rs2296336 ( ), if the true genotype frequencies were ourPp .000168
observed frequencies.
Figure 2. T1D association in the region centromeric to the MHC locus. The most signiﬁcant association lies within an intron of ITPR3.
The X-axis is indexed to base pairs of the May 2004 human genome build. Gray dots are values from the single most signiﬁcant of the
1,000 permutations of our survey data (the single iteration was the only 1 of 1,000 that produced such a peak). This visualization
permits an appreciation of the contours of the peak of signiﬁcance, which are much crisper in the peak derived from real data than
in the most signiﬁcant peak derived from the permutations. Although difﬁcult to quantify, this peak shape increases the signiﬁcance
of the survey result. Known genes from the UCSC genome browser are indicated at the top of the ﬁgure.
association, as judged by many researchers evaluating re-
ports of such associations that have been subsequently
been explained by conditioning on MHC class II geno-
types.13 Therefore, for this article, we must address infer-
ence for causal association from two perspectives: (1) that
ITPR3 lies near enough to the MHC to be in the category
of candidate genes that must be examined with excep-
tional care for linkage to an MHC haplotype and (2) that
ITPR3 lies in a genomic region distinct from the MHC.
The ﬁrst perspective requires additional tests to be per-
formed, so it is reasonable to separate discussion of these
perspectives for statistical as well as expository reasons.
It is known from prior studies that the MHC span of LD
ends telomeric to ITPR3, with the region of extended LD
in the MHC ending just centromeric to HLA-DPB1 (MIM
142858).28,29 We also veriﬁed this result in the Swedish
population we studied. In ﬁgure 1A, we plot r2 for all con-
trol individuals in our study. Two other observations are
consistent with this bound on LD. First, there is a known
recombination hotspot in this region (“R” in ﬁg. 1B).30
Second, presumably, a lack of selection pressure to main-
tain linkage allowed the mouse genome a syntenic break-
point (“S” in ﬁg. 1B) centromeric to TAPBP (MIM 601962)
with respect to other mammalian genomes. Together,
these lines of evidence suggest that it is unlikely that LD
plays a major role between HLA-DR/DQ and genes cen-
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Table 4. Epidemiology of ITPR3 T1D Risk
rs2296336 Attribute Finding
Risk allele (R) G
Protective allele (P) C
No. of cases with genotype:
R/R 107
R/P 296
P/P 240
No. of controls with genotype:
R/R 35
R/P 217
P/P 229
OR (95% CI) of RP:PP 1.3 (1.00–1.69)
OR (95% CI) of RR:PP 2.9 (1.88–4.59)
PAR percentage (95% CI) 21.2 (9.7–30.5)
NOTE.—Counts are the combined results of the
survey and validation studies. PAR is an estimate
of the percentage of T1D cases in the Swedish pop-
ulation that would not occur if all alleles of
rs2296336 were C, the protective allele.
tromeric to TAPBP. In particular, our data do not support
strong LD between ITPR3 and HLA-DR/DQ (e.g., 2r p
between rs2296336 and rs9272723). These lines of0.022
evidence suggest that it is appropriate to take the per-
spective that ITPR3 is in a region of the genome that is
distinct from the MHC locus.
However, in any given generation, ITPR3 and HLA-DR/
DQ haplotypes are fairly tightly maintained. Estimates
of linkage from NCBI Map Viewer include 0.96 cM
(deCODE), 2.2 cM (Genethon), and 0.55 cM (Marshﬁeld).
Over the course of the history of the Swedish population,
this proximity may have permitted genetic mechanisms,
possibly including currently unpostulated genetic mech-
anisms, to create a statistical correlation between these
loci that is unrelated to T1D causality. Simulations of ped-
igree linkage studies—but not association studies—have
produced associations at a distance from a selected vari-
ation in pedigree data sets with coarse marker density.31
Therefore, even though our data consist of high-density
SNP markers typed in a case-control association study in
a homogeneous population, caution is appropriate; it is
reasonable to take the perspective that ITPR3 should be
considered under the umbrella of the MHC locus. Con-
sidering all arguments together, we determined to proceed
with a validation study and then to perform two-locus
logistic regression between disease status and genotype
predictor variables, with both rs2296336 and each of
the MHC class II alleles included as predictor variables
in the model, but to limit the number of comparisons to
only those MHC class II alleles that associated more sig-
niﬁcantly with T1D than did rs2996336 in our study
population.
As part of our veriﬁcation study, sequencing was per-
formed on tiled PCR products across the region of peak
association,32 to detect all variation common to the risk
haplotype. We sequenced a 4,375-bp region from chro-
mosome 6 position 33743599 to position 33747974, in
10 individuals: 9 from the SCDS/DIS and 1 unaffected
non-Scandinavian white for reference DNA. The nine
SCDS/DIS samples included six cases and three controls.
All nine were predicted to be homozygous for the ITPR3
risk haplotype. In the sequenced 4,375-bp region,we iden-
tiﬁed no variable nonsynonymous SNPs. We did not iden-
tify any SNPs that were not previously reported in dbSNP.
However, we did identify SNPs in the risk haplotype that
had not been typed in our survey study. We therefore
included these in our veriﬁcation study (table 2).
To conﬁrm the association of ITPR3 with T1D, we ge-
notyped an additional 462 cases and 299 controls for 18
SNPs from our survey study as well as 10 additional SNPs
(table 2). The additional subjects were also from DIS and
SCDS and were distinct from the 363 individuals included
in our survey study.4,15 This veriﬁcation conﬁrmed our ini-
tially observed associations. For the most signiﬁcantly as-
sociated SNP from our survey study, rs2296336, the P value
computed from only the new data was , and31.89# 10
the P value from all combined 1,124 individuals was
(table 4).61.30# 10
If the peak of association in ITPR3 represents a causal
inﬂuence, such causality could be due a single SNP (or
other variation), either at the peak of association orwithin
a nearby region of LD, or due to multiple linked variations
in this region. We therefore employed PHASE (fastPHASE
Web site) to infer haplotypes among all survey cases and
controls.26 To limit computational complexity, we con-
strained our haplotype inferences to the eight survey SNPs
in ITPR3 with the most-signiﬁcant associations; these
SNPs span 12 kb. We saw 14 of 256 possible haplotypes;
of these, 5 make up 95% of all observed haplotypes (table
5). Only one of these ﬁve haplotypes includes the risk
allele of rs2296336. Construction of a maximum parsi-
mony cladogram divides these haplotypes into two clear
sets (ﬁg. 3). The Hamming distance (a measure of the
shortest mutational path between two strings) between
the closest two haplotypes in separate sets is 5. The two
most frequent haplotypes, one of which is the risk hap-
lotype, are complements of each other (i.e., they differ at
all eight SNPs), suggesting that they may be ancestral. The
diversity is more limited in the risk haplotype group than
in the protective haplotype group. If we deﬁne a biallelic
“synthetic genotype” based on whether an individual’s
predicted ITPR3 haplotypes belong to haplotype set 1
(risk) or set 2 (protective), the frequencies of these syn-
thetic genotypes in a T1D risk contingency table are
negligibly different from those of rs2296336; therefore,
rs2296336 makes an excellent tSNP for this haplotype and
risk for T1D, as would be the case if a variant of this SNP
were causal. We therefore present our analysis and dis-
cussion, using rs2296336 as a proxy for this haplotype.
As reported in previous publications, we have typing
information for HLA-DQA1, HLA-DQB1, and HLA-DRB1
for our samples, with major type available for nearly all
samples and with subtype available for most samples.16
We therefore computed single-point associations with
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Figure 3. Haplotype Hamming distances (HDs). The risk haplo-
type is in gray type, and the protective haplotypes are in black
type. Numbers in italics indicate the number of each haplotype
inferred from PHASE analysis to be present in the our set of cases
and controls. The tSNP rs2296336 is boxed. The Illumina allele
codes for each of the loci are as follows: rs2274200, ArA, GrB;
rs2296343, ArA, GrB; rs2296339, ArA, GrB; rs2296337, ArA,
GrB; rs1536036, ArA, GrB; rs2296336, CrA, GrB; rs2077163,
ArA, GrB; and rs2229634, ArA, GrB.
Table 5. Haplotypes at the ITPR3 Locus
Haplotype
Allele at SNP
No. of Haplotypes Predicted
by PHASE
rs2274200 rs2296343 rs2296339 rs2296337 rs1536036 rs2296336 rs2077163 rs2229634 Total
In
Patients
In
Controls
1 A A G G A C A A 13 11 2
2 A A G A A C A A 3 1 2
3 A G G G A C A A 1 0 1
4 A G G A A C A A 244 144 100
5 A G G A G C A A 2 0 2
6 A A G G A C A G 5 2 3
7 A A A G G G A G 149 70 79
8 A A A G G C A G 1 1 0
9 A A A G G G G G 27 14 13
10 A A G G A G G G 96 43 53
11 A G G G A G G G 2 1 1
12 G A A G G G G G 171 69 102
13 G A G G A G G G 2 1 1
14 G A G G G G G G 10 5 5
Total 726 362 364
NOTE.—Predicted haplotypes inferred from the eight most signiﬁcantly associated SNPs fall into two distinct sets. The “risk” set (haplotypes 1–
6) consists primarily of a single haplotype (4), whereas the “protective” set (haplotypes 7–14) has several common haplotypes. Haplotype 8,
predicted to occur only once, clusters with the other protective haplotypes (ﬁg. 3), but, since it shares the rs2296336 allele with the risk haplotype
set, it could be considered a risk haplotype. This table demonstrates that a single core haplotype is responsible for most of the association observed
between ITPR3 and T1D in Sweden. This haplotype most likely represents the state of these eight SNPs in the ancestral risk chromosome. The
Illumina allele codes for each of the loci are as follows: rs2274200, ArA, GrB; rs2296343, ArA, GrB; rs2296339, ArA, GrB; rs2296337, ArA,
GrB; rs1536036, ArA, GrB; rs2296336, CrA, GrB; rs2077163, ArA, GrB; and rs2229634, ArA, GrB.
T1D of each major type and subtype for these MHC class
II genes for the combined samples from our survey and
validation studies (table 6). We chose to speciﬁcallymodel
those with P values more signiﬁcant than the P value for
rs2296336—modeling each separately with rs2296336 in
a regression analysis to see if any one of these might ex-
plain the association with ITPR3 (table 6). In all cases of
conditioning on the 16 MHC class II predictors, the P
value for an effect on the regression of rs2296336 after
conditioning was .011. Thus, we can conclude that
rs2296336 is an independent predictor for risk of T1D.
However, at least some of the risk predicted by rs2296336
can be accounted for by MHC class II status (e.g., the
regression P value for rs2296336 alone is , but,62# 10
conditioned on the DQB1*0302 indicator, this P value be-
comes .01). This observation is consistent with a hypoth-
esis that ITPR3 has a weaker effect on T1D risk than does
MHC class II and is also consistent with a hypothesis of
an interaction between the effects of risk at both of these
loci, such as a particular variant that is required at both
loci for maximal risk.
We ﬁt our observed data to a standard set of regression
models (those implemented in LRASSOC). For each com-
parison, we selected the best model as the one with lowest
Akaike information content (AIC), subject to the con-
straint that it be at least 2 AIC units less than the next
best simpler model. The regression models include ADD1
(just rs2296336), ADD2 (just the other predictor), ADD
(both rs2296336 and the other predictor), DOM (adding
terms for homozygous effects), and ADDDOM (adding in-
teraction terms). If rs2296336had nothing to dowithT1D,
www.ajhg.org The American Journal of Human Genetics Volume 79 October 2006 623
Table 6. Association of MHC Class II Types and Subtypes
with T1D and Two-Locus Logistic Regression
Allele
Single-Point
Association P
Best
Two-Locus
Model
with
rs2296336
Regression P
for rs2296336
(ADD1 Model)
Regression P
for rs2296336
Conditioned
on Locus
(ADD Model)
rs9272723 7.92 # 1019 ADDDOM .000079 .000195
DQA1*01 3.40 # 1043 ADDDOM .000001 .000083
DQB1*0302 3.33 # 1035 DOM .000002 .010114
DRB1*15 4.68 # 1034 DOM .000003 .000021
DQB1*0602 1.77 # 1033 DOM .000002 .000014
DRB1*04 1.73 # 1026 DOM .000003 .003781
DQA1*03 1.77 # 1024 DOM .000001 .001643
DQA1*0102 4.98 # 1022 ADD .000001 .000005
DQB1*03 3.17 # 1020 ADD .000002 .000005
DRB1*03 7.31 # 1018 ADD .000003 .000001
DQB1*0603 7.95 # 1012 ADD .000002 .000005
DQA1*0103 2.48 # 1011 ADD .000001 .000002
DQB1*0301 2.44 # 109 ADD .000002 .000003
DQB1*02 2.68 # 108 DOM .000002 .000049
DRB1*13 5.20 # 108 ADD .000003 .000013
DQA1*05 9.28 # 108 DOM .000001 !.000001
DRB1*11 5.36 # 107 ADD .000003 .000005
NOTE.—MHC class II types and subtypes with association P values less
signiﬁcant than that of rs2296636 or with insufﬁcient diversity in our
study population to support regression analysis are not shown. Each MHC
allele is treated as a biallelic locus: either present, absent, or not typed.
Only individuals with unambiguous genotypes at both considered loci
were included in the regression models for each row; thus, since only
363 individuals were typed for rs9272723 in our survey, the P value for
rs2296336 is less signiﬁcant than the P values for other alleles that
were computed from more individuals. Regression of the most signiﬁcant
single-point SNP (rs9272723), which lies in an intron of HLA-DQA1, pro-
duces results that are consistent with regression with the MHC class II
predictors. Regression with DQA1*01 (or rs9272723) suggests that an in-
teractive term may be appropriate for modeling the risk associated with
ITPR3 and the MHC. The last column demonstrates that the T1D association
with rs2296336 remains signiﬁcant even when conditioned on an MHC
class II predictor. Tests are not independent (e.g., DQA1*0302 is a subset
of DQA1*03). A more extensive version of this table is available at T1DBase.
Table 7. Contingency Table for ITPR3 and
HLA-DQA1*01
ITPR3 DQA1*01 No. of Cases No. of Controls
R/R / 5 0
R/R / 24 25
R/R / 5 79
R/P / 34 8
R/P / 90 85
R/P / 83 194
P/P / 44 5
P/P / 119 69
P/P / 62 156
NOTE.— ; . P p protec-2 16x p 204.6 P ! 2.2 # 10
tive allele; R p risk allele. The combination of ho-
mozygous risk alleles for both ITPR3 and DQA1*01
(top line) increases the risk for T1D over other ge-
notypes. This table is representative of the set of
contingency tables for ITPR3 and a highly associated
MHC class II type or subtype (all contingency tables
are available at T1DBase—ITPR3). To minimize the
number of estimated variables for regression analysis,
each DQA allele is coded as one of only two possi-
bilities: the allele is DQA1*01 () or is not DQA1*01
(). Separate contingency tables were computed in
a similar fashion for each typed class II locus and
allele.
then the best model selected by LRASSOC should be
ADD2. ADD2 is never observed to be the best model, nor
is ADD1. All the best models observed employ both pre-
dictors. The DOM model would be predicted for classic
epistasis between the loci. The ADD model would be pre-
dicted if both loci contributed to risk independently. The
ADDDOM model would be predicted if particular variants
at each loci were both required for risk, as might be the
case if the products of these variants interacted with each
other. However, the converses of these predictions are not
necessarily true (e.g., it is not the case that, if the best
model is ADDDOM, then the products of the loci interact).
Regression with DQA1*01, which yielded the most sig-
niﬁcant T1D association with an MHC class II predictor
in single-point analysis, suggests that an interactive term
may be appropriate in modeling risk when the combi-
nation of ITPR3 and MHC effects on T1D are considered;
ADDDOM was the best model. Each of these analyses is
based on data summarized by a contingency table9# 2
and yields a linear model for predicting the proportion of
those with a given multilocus genotype who represent
cases rather than controls. As an example, the contin-
gency table for DQA1*01 is provided (table 7), and a com-
parison of the results of the regression model with the
observed ratios is shown in ﬁgure 4. In all contingency
tables produced for these regression analyses, homozy-
gosity for the risk variants of both predictors produces the
highest risk, although data for this double homozygous
genotype are fairly sparse. The ORs of homozygous risk
genotypes compared with homozygous protective geno-
types computed from these two-locus contingency tables
tend to approximate the product of the two single-locus
ORs computed separately (supplemental data are available
at T1DBase—ITPR3).
In addition to comparisons with the MHC class II genes
as typed using traditional approaches, we also tested a two-
locus regression model between disease status and two
genotype predictor variables: rs2296336 and the most sig-
niﬁcant single-point SNP fromour survey data (rs9272723,
which lies in an intron of HLA-DQA1), although this re-
quired limiting the number of individuals for regression
to the 363 individuals tested in our survey (table 6). Re-
gression with rs9272723 produces results that are consis-
tent with regression results based on HLA-DQA1. This re-
sult suggests that typing of noncoding MHC SNPs has at
least limited value in reﬂecting risk factors that are asso-
ciated with variation in MHC class II coding regions.
To further explore evidence of independent mecha-
nisms of action of the HLA-DR/DQand ITPR3 associations,
we examined the correlation of the age-at-onset pheno-
type with genotype. Age at onset of T1D is known to cor-
relate with HLA-DR/DQ.4,16 In our data, for example, the
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Figure 4. Regression analysis for predicting the proportion that
are cases versus controls, given the genotype, with rs2296336 and
HLA-DQA1*01 status as predictor variables. P p protective allele
of ITPR3; R p risk allele of ITPR3;  p DQA1*01 present;  p
DQA1*01 absent.
mean age at onset in case patients with a homozygous
protective HLA-DR/DQ haplotype is 21.5 years but drops
to 15.7 years for the homozygous risk haplotype (Pp
). However, the association at ITPR3 does not correlate.030
with age at onset ( ). The different correlation withPp .64
age supports the hypothesis that theMHC and ITPR3 have
independent mechanisms contributing to T1D risk.
Discussion
The biology of ITPR3 makes ITPR3 an excellent candidate
gene. ITPRs mediate second messenger signaling by re-
leasing Ca from intracellular stores in response to ino-
sitol triphosphate. There are three ITPR subtypes, and
these are widely expressed inmany tissues, consistentwith
their role in mediating second messenger signaling. Each
of the subtypes has a unique tissue-distribution proﬁle.
ITPR3 mRNA and ITPR3 protein are rapidly upregulated
in pancreatic b cells following stimulation with glucose,
and the protein is then rapidly degraded in proteasomes.33
ITPR3 mRNA is one of the most strongly upregulatedmes-
sages in this system. Srivastava et al.34 showed that the
Anx7/ knockout mouse model had reduced ITPR3 ex-
pression in the endoplasmic reticulum of pancreatic b
cells, which caused defects in Ca-dependent insulin se-
cretion. There is no report of the phenotype of the single
Itpr3 knockout, but the double Itpr2/Itpr3 knockoutmouse
is reported to be hypoglycemic and lean and to have im-
paired exocrine function.35 Thus, ITPR3 is, in a biological
context, consistent with a causal association with T1D.
Variation at rs2296336may inﬂuence risk for T1D through
an effect on alternative splicing, since themost signiﬁcant
variations of the rs2296336 haplotype lie within introns
of ITPR3.
The combination of high-throughput genotyping, the
completed genome sequences of human and mouse, the
availability of cases and controls from homogeneous pop-
ulations, linkage studies that permit targeting particular
loci for ﬁne-scale analysis, andmature bioinformatics soft-
ware and algorithms has increasingly made the discovery
of variation contributing to complex diseases possible. For
example, the ﬁndings of associations of IFIH1 (MIM
606951) with T1D, TCF7L2 (MIM 602228) with T2D, and
INSIG2 (MIM 608660) with obesity (MIM 601665) repre-
sent examples of such success.36–38 In association studies,
P values for common variants that moderately inﬂuence
risk may be less signiﬁcant than those for rare variants
that drastically inﬂuence risk. This phenomenon is ob-
served in ﬁgure 1C, in which rare alleles of HLA-DR/DQ
that confer near-absolute protection from T1D are at least
somewhat responsible for a relatively signiﬁcant statistical
association compared with that of ITPR3. Nevertheless,
both of these genes may have comparable inﬂuences on
public health in Sweden. Detection of such genes seems
to be possible with studies comprising between 300 and
1,200 individuals and with marker resolutions between 3
and 46 kb (in our study and the study of Grant et al.,37
respectively). However, in our study, the effective haplo-
type block length for the ITPR3 association is ∼13 kb. The
implications for future mapping projects may be that, to
ﬁnd more associations for many disease genes, the search
must be performed at a resolution !13 kb. High-resolution
mapping can (1) provide precision, possibly limiting the
number of candidate genes to exactly one and possibly
even identifying the causal coding SNP; (2) ﬁnd associa-
tions missed by coarser association studies; and (3) resolve
nearby independent associations in complex multigenic
disorders that, in a more coarse study, would have been
lumped as a single association. To ﬁnd all genes contrib-
uting to complex disorders, it may, in fact, be necessary
to perform such mapping for every candidate gene and
perhaps for the entire genome.
We remain cautious in interpreting association as evi-
dence of causality. In the event that causality between
ITPR3 and T1D is ever disproved, then our results may
possibly retain some interest, in that, at least within the
Swedish population, genotyping of ITPR3 together with
other assays may represent a convenient method of eval-
uating T1D risk as a proxy for actual causal variation. If
one accepts the argument that the peak of association
centered in the ITPR3 gene is due at least in part to the
inﬂuence on phenotype of a nearby variation and is
not due entirely to inﬂuence on phenotype from long-
distance correlation with variation within the MHC locus,
one might still consider rejecting the argument that the
nearby phenotypic inﬂuence must necessarily be due to
alteration in the function of ITPR3. If ITPR3 is itself not
causal, but yet there is a nearby casual genetic variation,
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then any of the genes in the 3.1-Mb mouse interval Idd16
would be a candidate.12 IHPK3 (MIM 606993), centromeric
to ITPR3, plays a role in inositol triphosphatemetabolism.
C6orf125 lies between ITPR3 and IHPK3. We believe that
one of the most valuable contributions of ﬁne-scale SNP
association mapping is that it provides data that can be
visualized such that clearly deﬁned and sharp peaks of
association can be seen. We see such a sharp peak of as-
sociation within a speciﬁc domain of the ITPR3 gene in
ﬁgure 2. This peak lies entirely within the ITPR3 gene and
points like an arrow to the TRPC3 (MIM 602345) binding
domain.39 Variation in nearby unidentiﬁed genes or reg-
ulatory sequences may also be at play.40 Follow-up by
many labs at many levels, ultimately including clinical
studies, will be necessary to conﬁrm that ITPR3 is more
than a candidate T1D gene and to understand the possible
role of nearby genes. A systems-biology analysis thatmore
fully places ITPR3 in the contextual model for T1D, as well
as typing of ITPR3 variation in other populations, may aid
such a process.
Our discovery of ITPR3 as a T1D-associated gene in close
association with HLA-DR/DQ does not represent the ﬁrst
time a non-MHC gene in or near the MHC locus has been
associated with disease. For example, the gene associated
with 21-hydroxylase deﬁciency (MIM 201910) was iden-
tiﬁed in the 1980s.41 We doubt ITPR3 will be the last such
gene. The high density of genes in the MHC may be due,
in part, to paired interaction of linkage and selection (also
known as “hitchhiking”), which is what we theorize HLA-
DR/DQ and ITPR3 may share.42,43 The hint of an interac-
tion term in our regression analysis (table 6) is consistent
with such a model.44 Observed interactions between the
effects of genes may be facilitated by overdominant se-
lection or heterozygote advantage, as has been observed
already in the MHC.45
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